A not so common side e¡ect of chemotherapy is the appearance of onycholysis. We here describe such a case.
DISCUSSION
In the case described, no nail alterations were noted after the administration of CHOP but only after the administration of CNOP^Bleo. These two regimens being identical with the exception of mitoxantrone and bleomycin, it seems very likely that onycholysis was caused by the administration of mitoxantrone. To the best of our knowledge this antineoplastic agent has been associated with onycholysis in exceptionally few subjects (1, 2). Another alteration attributed to mitoxantrone is ungual discoloration (3) . Bleomycin on the other hand has been associated only with nail pigmentation (4) and has been administered in clinical practice for a much longer time than mitoxantrone.
Mitoxantrone is actually included in standard combination chemotherapy regimens for various neoplastic diseases, such as non-Hodgkin's lymphoma, breast cancer and prostate cancer. As it is used more often one should be aware of its possible side e¡ects.
